Based in Las Vegas, GB Sciences, Inc. (OTCQB: GBLX) is pursuing a federally-registered trial in humans by using cannabis-based therapies for the treatment of early to moderate Parkinson’s disease.
GB Sciences, which deals with cannabis production as well as biopharmaceutical research, is eying a federal route for its initial trial to fasten the process.
GB Sciences said in a statement:
“Performing an FDA-Registered clinical trial, instead of a Nevada-based pilot trial as reported earlier, also translates to quicker entry into international markets with harmonized regulatory standards.”
Federally, medical marijuana is not seen as a real alternative as that of conventional, pharmaceutical medicine. However, pursuing a trial registered by the Food and Drug Administration (FDA), the federal agency of the United States Department of Health and Human Services, shows how the growing trend of marijuana legalization is gaining strong momentum.
The company acknowledges that it will be “more difficult” to register the First-in-Human trial with the FDA at the time being but it said: “The longer-term benefits for the patients and GB shareholders should be great.”
In late March, the first U.S. publicly traded cannabis company Medical Marijuana, Inc. has agreed to help a Brazilian university research if cannabis can help Parkinson’s patients.
For more details about the GB Sciences’ clinical trial, click HERE.